Shah Deep, Osipo Clodia
Department of Molecular Pharmacology and Therapeutics, Oncology Research Institute, Loyola University Chicago, Maywood, IL 60153, USA.
Department of Microbiology and Immunology, Oncology Research Institute, Loyola University Chicago, Maywood, IL 60153, USA.
Genes Dis. 2016 Jun;3(2):114-123. doi: 10.1016/j.gendis.2016.02.002. Epub 2016 Feb 21.
Human Epidermal Growth Factor Receptor type 2 (HER2) gene amplification and/or protein overexpression is observed in patients suffering from HER2+ breast cancer. This subtype of breast cancer has improved prognosis due to availability of anti-HER2 therapy. However, drug resistance and tumor recurrence still remains a major concern. Cancer Stem Cells (CSCs) are believed to constitute the subset of cell population that is resistant to drug treatment and possesses characteristics of stem cells. CSCs enable the tumors to thrive despite major insults. This review provides a comprehensive idea about the concept of CSCs in context of HER2+ breast cancer by providing the description of the markers that are used for the identification of CSCs and by elucidating the signaling pathways that are associated with HER2+ breast CSCs. Furthermore, the review also describes the interaction of HER2 with those signaling pathways and the future of targeting CSCs in HER2+ breast cancer.
在HER2阳性乳腺癌患者中观察到人类表皮生长因子受体2（HER2）基因扩增和/或蛋白过表达。由于抗HER2治疗的出现，这种乳腺癌亚型的预后有所改善。然而，耐药性和肿瘤复发仍然是一个主要问题。癌症干细胞（CSCs）被认为是细胞群体中的一个子集，对药物治疗具有抗性，并具有干细胞的特征。尽管受到重大损伤，癌症干细胞仍能使肿瘤茁壮成长。本综述通过描述用于识别癌症干细胞的标志物，并阐明与HER2阳性乳腺癌干细胞相关的信号通路，全面介绍了HER2阳性乳腺癌中癌症干细胞的概念。此外，该综述还描述了HER2与这些信号通路的相互作用以及HER2阳性乳腺癌中靶向癌症干细胞的未来。
